

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/006937 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/036090

(22) International Filing Date:
28 June 2024 (28.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/511,187 30 June 2023 (30.06.2023) US
63/591,868 20 October 2023 (20.10.2023) US
63/557,370 23 February 2024 (23.02.2024) US
63/654,508 31 May 2024 (31.05.2024) US

(71) Applicants: **SPARK THERAPEUTICS, INC.** [US/US];
3737 Market Street, Suite 1300, Philadelphia, PA 19104
(US). **GENENTECH, INC.** [US/US]; 1 Dna Way, South
San Francisco, CA 94080 (US).

(72) Inventors: **CALI, Christopher**; c/o Spark Therapeutics,
Inc., 3737 Market Street, Suite 1300, Philadelphia, PA
19104 (US). **CARGNIN, Francesca**; c/o Spark Therapeu-
tics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA
19104 (US). **HALEY, Benjamin, J.**; c/o Genentech, Inc., 1
Dna Way, South San Francisco, CA 94080 (US). **SAVOLA,
Juha**; c/o Spark Therapeutics, Inc., 3737 Market Street,
Suite 1300, Philadelphia, PA 19104 (US). **LI, Quanyi**; c/o
Spark Therapeutics, Inc., 3737 Market Street, Suite 1300,
Philadelphia, PA 19104 (US). **LI, Mathew, Maoxiang**; c/
o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300,
Philadelphia, PA 19104 (US). **PRICE, Philip, Lee**; c/o
Spark Therapeutics, Inc., 3737 Market Street, Suite 1300,
Philadelphia, PA 19104 (US). **RAMSBURG, Elizabeth**; c/
o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300,
Philadelphia, PA 19104 (US).

(74) Agent: **HEBER, Sheldon, O.** et al.; Ice Miller LLP, 1735
Market Street, Suite 3900, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: INHIBITORY RNA TARGETING HUNTINGTIN EXPRESSION

(57) Abstract: The present invention features RNA polynucleotide constructs comprising sequences targeting Huntingtin mRNA, polynucleotide constructs comprising a sequence encoding for such RNA constructs, and primary microRNA scaffolds. Constructs comprising sequences targeting Huntingtin mRNA and/or encoding for sequences targeting Huntingtin mRNA can be used, for example, for inhibiting mutant HTT expression and/or treating Huntington disease.

WO 2025/006937 A2